Exploring combined therapeutic strategies: S-adenosylmethionine (SAM) and conventional medications in polycystic ovary syndrome (PCOS) management

Abstract

Polycystic Ovary Syndrome (PCOS) remains a prevalent endocrine disorder among women of reproductive age, with treatments often facing significant limitations. This research article delves into an innovative therapeutic strategy that bridges the potential epigenetic capabilities of S-adenosylmethionine (SAM) with the established benefits of traditional PCOS medications, notably metformin and contraceptive pills. Drawing inspiration from contemporary literature, the manuscript highlights the limited role of SAM in DNA methylation processes and the unclear long-term effects of Sam in attenuating PCOS-related traits in specific animal models. The paper meticulously outlines an experimental design, encapsulating aspects such as precise drug formulation, systematic administration regimens, and methodical data collection and analysis techniques. Such a holistic approach facilitates a robust evaluation of the synergetic effects of combining SAM with established drugs. In spotlighting this combined therapeutic method, the article aspires to offer fresh perspectives in the realm of PCOS management, ultimately emphasizing the pivotal importance of subsequent clinical trials and more extensive studies in solidifying these preliminary findings.